JP2016523862A - ハンチントン病を治療するための高用量プリドピジンの使用 - Google Patents

ハンチントン病を治療するための高用量プリドピジンの使用 Download PDF

Info

Publication number
JP2016523862A
JP2016523862A JP2016521580A JP2016521580A JP2016523862A JP 2016523862 A JP2016523862 A JP 2016523862A JP 2016521580 A JP2016521580 A JP 2016521580A JP 2016521580 A JP2016521580 A JP 2016521580A JP 2016523862 A JP2016523862 A JP 2016523862A
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
uhdrs
pridopidine
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016521580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523862A5 (enExample
Inventor
バッサン、メラブ
エイアル、エリ
ハガイ、エスザー・ルカジービック
スバインスドッター・タイゲ・ビッケンベルグ、アンナ・クリスティーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016523862(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Publication of JP2016523862A publication Critical patent/JP2016523862A/ja
Publication of JP2016523862A5 publication Critical patent/JP2016523862A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016521580A 2013-06-21 2014-06-19 ハンチントン病を治療するための高用量プリドピジンの使用 Withdrawn JP2016523862A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US61/837,928 2013-06-21
US201361877832P 2013-09-13 2013-09-13
US61/877,832 2013-09-13
PCT/US2014/043204 WO2014205229A1 (en) 2013-06-21 2014-06-19 Use of high dose pridopidine for treating huntington's disease

Publications (2)

Publication Number Publication Date
JP2016523862A true JP2016523862A (ja) 2016-08-12
JP2016523862A5 JP2016523862A5 (enExample) 2017-08-03

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521580A Withdrawn JP2016523862A (ja) 2013-06-21 2014-06-19 ハンチントン病を治療するための高用量プリドピジンの使用

Country Status (24)

Country Link
US (1) US10322119B2 (enExample)
EP (1) EP3010506B1 (enExample)
JP (1) JP2016523862A (enExample)
KR (1) KR102316933B1 (enExample)
CN (1) CN105592848A (enExample)
AU (1) AU2014281414A1 (enExample)
BR (1) BR112015029918A2 (enExample)
CA (1) CA2913781C (enExample)
CL (1) CL2015003690A1 (enExample)
DK (1) DK3010506T3 (enExample)
EA (1) EA201690069A1 (enExample)
ES (1) ES2879631T3 (enExample)
HK (1) HK1221646A1 (enExample)
HU (1) HUE054783T2 (enExample)
IL (1) IL242804B (enExample)
MX (1) MX384234B (enExample)
PE (2) PE20170302A1 (enExample)
PH (1) PH12015502691A1 (enExample)
PL (1) PL3010506T3 (enExample)
SG (1) SG11201509729YA (enExample)
TW (1) TW201529069A (enExample)
UA (1) UA122999C2 (enExample)
UY (1) UY35624A (enExample)
WO (1) WO2014205229A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524897A (ja) * 2016-08-24 2019-09-05 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
JP2019524898A (ja) * 2016-08-24 2019-09-05 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
JP2020532517A (ja) * 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
JP2022521457A (ja) * 2019-01-31 2022-04-08 エフ．ホフマン－ラ ロシュ アーゲー ハンチントン病の進行度の評価方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2937243C (en) * 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
EP3324967A4 (en) * 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
AU2017326436A1 (en) * 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
US20260091028A1 (en) * 2017-08-14 2026-04-02 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
HUE061505T2 (hu) * 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
SMT202600016T1 (it) * 2019-06-12 2026-03-09 Prilenia Neurotherapeutics Ltd Composizione contenente pridopidina e un suo analogo per il trattamento della malattia di huntington e dei suoi sintomi
CN114727761A (zh) * 2019-09-17 2022-07-08 豪夫迈·罗氏有限公司 患有运动障碍的患者的个性化保健的改善
CN116472043A (zh) 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
WO2022094565A1 (en) * 2020-10-28 2022-05-05 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders
CA3214354A1 (en) * 2021-04-14 2022-10-20 Michael Hayden Treatment of prodromal huntington disease
WO2025181805A1 (en) * 2024-02-27 2025-09-04 Prilenia Neurotherapeutics Ltd. Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
EP1815857A1 (en) * 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US20150209346A1 (en) 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015003812A (es) 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524897A (ja) * 2016-08-24 2019-09-05 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
JP2019524898A (ja) * 2016-08-24 2019-09-05 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
JP2021119189A (ja) * 2016-08-24 2021-08-12 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
JP2021119186A (ja) * 2016-08-24 2021-08-12 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
JP7278327B2 (ja) 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
JP7278210B2 (ja) 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
JP2020532517A (ja) * 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
JP2022521457A (ja) * 2019-01-31 2022-04-08 エフ．ホフマン－ラ ロシュ アーゲー ハンチントン病の進行度の評価方法

Also Published As

Publication number Publication date
MX384234B (es) 2025-03-14
PH12015502691A1 (en) 2016-03-14
KR102316933B1 (ko) 2021-10-26
ES2879631T3 (es) 2021-11-22
CA2913781C (en) 2022-05-10
EP3010506B1 (en) 2021-05-12
HK1221646A1 (zh) 2017-06-09
UY35624A (es) 2015-01-30
DK3010506T3 (da) 2021-07-12
WO2014205229A1 (en) 2014-12-24
US20140378508A1 (en) 2014-12-25
CL2015003690A1 (es) 2016-10-28
HUE054783T2 (hu) 2021-09-28
UA122999C2 (uk) 2021-02-03
WO2014205229A8 (en) 2015-04-09
IL242804B (en) 2022-02-01
CN105592848A (zh) 2016-05-18
MX2015017307A (es) 2016-08-03
PL3010506T3 (pl) 2021-11-02
CA2913781A1 (en) 2014-12-24
EP3010506A4 (en) 2017-02-08
AU2014281414A1 (en) 2016-01-21
KR20160055122A (ko) 2016-05-17
BR112015029918A2 (pt) 2017-07-25
SG11201509729YA (en) 2015-12-30
US10322119B2 (en) 2019-06-18
EA201690069A1 (ru) 2016-06-30
PE20170302A1 (es) 2017-03-31
TW201529069A (zh) 2015-08-01
EP3010506A1 (en) 2016-04-27
PE20160195A1 (es) 2016-05-14

Similar Documents

Publication Publication Date Title
KR102316933B1 (ko) 헌팅턴병 치료를 위한 프리도피딘의 용도
US20250360121A1 (en) Pridopidine for treating huntington's disease
US20250352533A1 (en) Pridopidine for treating huntington's disease
JP7278327B2 (ja) ジストニアを治療するためのプリドピジンの使用
JP6912574B2 (ja) 機能低下を治療するためのプリドピジンの使用
Banaschewski ADHD and hyperkinetic disorder
JP2022524008A (ja) うつ病の治療のためのエスケタミン
CA3153856A1 (en) Intranasal administration of esketamine
EP3893876A1 (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
Handen et al. Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders
US20240261237A1 (en) Reducing side effects of nmda receptor antagonists
CA3240774A1 (en) Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
Bharucha et al. Assessment of behavioral and psychological symptoms of dementia
CN119654149A (zh) 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法
US20240050408A1 (en) Use of mglur5 antagonists for treating amphetamine addiction
Class et al. Patent application title: PRIDOPIDINE FOR TREATING HUNTINGTON'S DISEASE
WO2013142162A1 (en) Method of treating bladder disorders
HK1224215A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
Koran Treatment of patients with obsessive-compulsive disorder
EA041256B1 (ru) Применение придопидина для лечения ухудшения функциональной способности
MARLBOROUGH Diagnostic and Statistical Manual of Mental Disorders, Text Revision. In this study, Vyvanse demonstrated a reduction (approximately 52%)
EA039995B1 (ru) Применение придопидина для лечения болезни хантингтона
MARLBOROUGH SEPRACOR PROVIDES UPDATE ON CLINICAL TRIALS FOR SEP-225289 AND LUNESTA PEDIATRICS

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20161013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170622

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180115